Zhibo Ma, PhD of @salkinstitute answers common questions asked by colleagues regarding measuring chromatin accessibility changes in breast cancer.
________
Breast cancer is one of the most common cancers, and some types are among the hardest to treat. The different types and presence of many different cells makes it difficult to target these tumors. Scientists at the Salk…
FDA approves combination treatment for advanced non-small cell lung cancer (NSCLC) targeting specific EGFR mutations. Learn about the MARIPOSA trial results,…
FDA approved pembrolizumab (Keytruda) combined with chemotherapy for mesothelioma treatment. A new option for patients battling this aggressive disease.
FDA approves Kisqali for early high-risk breast cancer treatment. Learn about this new treatment option and its benefits for patients.
Download Slides: https://oncologytube.com/slides-fda-approves-kisqali-ribociclib-for-early-high-risk-breast-cancer/The FDA has approved Kisqali (ribociclib) …
Promising results from the TIGIT combination therapy trial presented at ESMO 2024. Discover the potential of this treatment for lung cancer.
In this video, we explore the FDA approval of Genentech’s Tecentriq Hybreza, the first subcutaneous anti-PD-(L)1 immunotherapy for cancer. Approved on Septem…
AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered Paper oral presentation at the…
Dr. Nathalie M. Johnson, MD, discusses the importance of adopting ctDNA testing in breast cancer management. Find out how it can benefit patients with high-risk…
Exciting news in endometrial cancer treatment: FDA approves dostarlimab-gxly for broader patient population. Learn about the clinical trial and its positive results.
Discover the problem of underutilization of genetic testing in cancer. Find out how it can lead to missed opportunities for early intervention.
